<DOC>
	<DOC>NCT01977131</DOC>
	<brief_summary>The aim of this study was to analyze the safety, pulmonary function, and imaging changes of patients with silicosis treated with autologous bone marrow stromal cells with modification by hepatocyte growth factor.</brief_summary>
	<brief_title>Safety Study of Autologous Bone Marrow Stromal Cells With Modification by Hepatocyte Growth Factor to Treat Silicosis</brief_title>
	<detailed_description />
	<mesh_term>Silicosis</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>age between 1850, chronic and accelerated silicosis, characterized with a fibrotic increase in the last two years, FEV1 &lt;60% and &gt; 40%, FVC &gt; 60% and SaO2 &gt;90% smoking, active tuberculosis or other infections, cancer, autoimmune disorders, hematological, hepatic or cardiac diseases, and pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>